Stock CADL CANDEL THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

News Candel Therapeutics, Inc.

Equities

CADL

US1374041093

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
7.8 USD -27.03% Intraday chart for Candel Therapeutics, Inc. -32.17% +430.61%
May. 23 Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting CI
Apr. 11 Sector Update: Health Care Stocks Decline Thursday Afternoon MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Candel Therapeutics : Corporate Presentation - May 2024
PU
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of Can-2409 for Advanced Non-Small Cell Lung Cancer in Patients Non-Responsive to Immune Checkpoint Inhibitor Treatment At 2024 Asco Annual Meeting
CI
Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual Meeting
GL
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
GL
Candel Therapeutics to Present at the Jefferies Global Healthcare Conference
AQ
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
GL
Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual Meeting
AQ
Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
GL
Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual Meeting
GL
Autonomix Medical Inc Covered in Benzinga Article Highlighting Innovative Nerve Treatment Tech
AQ
Sector Update: Health Care Stocks Decline Thursday Afternoon
MT
Candel Therapeutics Shares Rise After FDA Orphan Drug Designation for Potential Pancreatic Cancer Drug
MT
Candel Therapeutics Shares Leap Premarket on FDA Orphan-Drug Designation
DJ
Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic Cancer
GL
Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
GL
Candel Therapeutics Presents Preclinical Data At Aacr on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid Tumors
CI
March Jobs Growth Exceed Expectations, Lifting US Equity Futures Pre-Bell
MT
Sector Update: Health Care Stocks Lean Higher Pre-Bell Friday
MT
Jobs Data Awaited as Exchange-Traded Funds, Equity Futures Rise Pre-Bell Friday
MT
Top Premarket Gainers
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CADL Stock
  4. News Candel Therapeutics, Inc.